Hideyoshi Harashima Selected Research

Matrix Metalloproteinase 14 (MT1-MMP)

9/2007	Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
5/2007	In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hideyoshi Harashima Research Topics

Disease

92	Neoplasms (Cancer) 09/2022 - 10/2005
16	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 02/2007
9	Renal Cell Carcinoma (Grawitz Tumor) 05/2022 - 01/2012
7	Urinary Bladder Neoplasms (Bladder Cancer) 12/2018 - 03/2009
6	Neoplasm Metastasis (Metastasis) 05/2022 - 09/2013
6	Body Weight (Weight, Body) 10/2021 - 08/2011
5	Obesity 10/2021 - 10/2012
5	Type 2 Diabetes Mellitus (MODY) 03/2014 - 12/2003
4	Bites and Stings (Sting) 01/2021 - 06/2014
4	Infections 01/2021 - 01/2013
4	Brain Diseases (Brain Disorder) 01/2018 - 01/2014
3	Fibrosis (Cirrhosis) 05/2022 - 03/2021
3	Melanoma (Melanoma, Malignant) 01/2021 - 03/2011
3	Insulin Resistance 03/2016 - 06/2015
3	Carcinogenesis 06/2011 - 12/2006
2	COVID-19 01/2022 - 10/2021
2	Cardiomyopathies (Cardiomyopathy) 01/2020 - 10/2018
2	Colitis 12/2018 - 07/2016
2	Lymphoma (Lymphomas) 03/2016 - 02/2015
2	Reperfusion Injury 12/2015 - 09/2015
2	Hypersensitivity (Allergy) 06/2011 - 05/2011
2	Tuberculosis (Tuberculoses) 06/2011 - 05/2011
2	Carcinoma (Carcinomatosis) 06/2011 - 03/2009
2	Genomic Instability 03/2008 - 03/2003
1	Bone Resorption 01/2022
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2022
1	Osteolysis 01/2022
1	Weight Gain 01/2022
1	Heart Failure 01/2022
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022
1	Heart Diseases (Heart Disease) 01/2022

Drug/Important Bio-Agent (IBA)

37	Small Interfering RNA (siRNA)IBA 09/2022 - 05/2009
24	Liposomes (Liposome)IBA 01/2022 - 10/2005
19	LipidsIBA 05/2022 - 10/2007
18	Pharmaceutical PreparationsIBA 01/2022 - 02/2007
18	LigandsIBA 01/2022 - 11/2011
15	Peptides (Polypeptides)IBA 01/2019 - 10/2005
14	Lipid NanoparticlesIBA 01/2022 - 06/2011
11	DNA (Deoxyribonucleic Acid)IBA 09/2022 - 03/2003
10	Proteins (Proteins, Gene)FDA Link 04/2015 - 12/2006
9	Messenger RNA (mRNA)IBA 09/2022 - 12/2003
9	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 09/2007
8	AntigensIBA 01/2022 - 05/2011
8	Mitochondrial DNA (mtDNA)IBA 01/2021 - 10/2008
6	Nucleic AcidsIBA 01/2022 - 01/2010
5	Therapeutic UsesIBA 05/2022 - 06/2011
5	Matrix Metalloproteinases (MMPs)IBA 12/2016 - 05/2007
5	Tuberculin (PPD)IBA 06/2011 - 10/2007
4	InterferonsIBA 01/2021 - 06/2014
4	RNA (Ribonucleic Acid)IBA 11/2020 - 01/2010
4	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2020 - 05/2009
4	octaarginineIBA 11/2019 - 03/2009
4	Hyaluronic Acid (Hyaluronan)IBA 10/2019 - 06/2015
4	CytokinesIBA 11/2017 - 05/2011
4	Insulin (Novolin)FDA Link 03/2016 - 12/2006
4	YSK05IBA 10/2015 - 06/2013
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2020 - 12/2016
3	Vitamin E FDA LinkGeneric 01/2020 - 02/2015
3	Cell-Penetrating PeptidesIBA 01/2017 - 08/2012
3	bis(3',5')-cyclic diguanylic acidIBA 12/2016 - 06/2014
3	Blood Glucose (Blood Sugar)IBA 01/2016 - 03/2014
3	Interferon Type IIBA 10/2015 - 06/2014
3	Nucleotide AptamersIBA 08/2014 - 01/2012
3	Cell Wall SkeletonIBA 02/2014 - 06/2011
3	liposomal doxorubicin (Doxil)FDA Link 07/2013 - 02/2007
2	Adenosine Triphosphate (ATP)IBA 01/2022 - 06/2014
2	VaccinesIBA 01/2022 - 01/2022
2	cytidylyl-(3'-5')-cytidine (CpC)IBA 01/2022 - 10/2018
2	Sorafenib (BAY 43-9006)FDA Link 10/2021 - 01/2019
2	MidkineIBA 10/2021 - 01/2019
2	Immune Checkpoint InhibitorsIBA 01/2021 - 11/2020
2	Photosensitizing Agents (Photosensitizers)IBA 01/2020 - 01/2020
2	PorphyrinsIBA 01/2020 - 01/2020
2	OvalbuminIBA 12/2018 - 01/2017
2	Myristic Acid (Tetradecanoic Acid)IBA 12/2018 - 02/2015
2	Dextran SulfateIBA 12/2018 - 07/2016
2	Nanoparticle Drug Delivery SystemIBA 11/2017 - 12/2016
2	coenzyme Q10 (CoQ10)IBA 01/2017 - 09/2015
2	cyclic arginine-glycine-aspartic acid peptideIBA 01/2016 - 09/2015
2	Triglycerides (Triacylglycerol)IBA 01/2016 - 03/2014
2	Glucose (Dextrose)FDA LinkGeneric 06/2015 - 09/2013
2	Biomarkers (Surrogate Marker)IBA 08/2014 - 01/2012
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2014 - 02/2007
2	LeptinIBA 10/2013 - 03/2013
2	Matrix Metalloproteinase 14 (MT1-MMP)IBA 09/2007 - 05/2007
1	BiglycanIBA 05/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022
1	Annexin A1IBA 01/2022
1	Toll-Like Receptor 3IBA 01/2022

Therapy/Procedure

43	Therapeutics 05/2022 - 10/2005
21	Immunotherapy 01/2022 - 03/2009
5	Transplantation 01/2022 - 09/2013
3	Photochemotherapy (Photodynamic Therapy) 01/2020 - 08/2008
3	Intravenous Administration 01/2020 - 10/2007
3	Drug Therapy (Chemotherapy) 02/2015 - 01/2014
2	Injections 01/2022 - 01/2014
2	Cell Transplantation 01/2022 - 01/2020
2	Lab-On-A-Chip Devices 10/2021 - 01/2017
2	Lasers (Laser) 01/2017 - 03/2009
1	Arthroplasty 01/2022